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Cushing’s syndrome (CS) has been reported secondary to an 
interaction between inhaled/intranasal fluticasone and low 
dose ritonavir as well as other protease inhibitors (PIs) which 
results in steroid accumulation, adrenal suppression and florid 
CS.1-4
There are 4 case reports of pseudo-Cushing’s syndrome (p-
CS) in patients taking PIs though definitive causality could not 
be determined as therapy was maintained in the interest of 
virologic control.5
To our knowledge, p-CS in a HIV- infected patient secondary to 
darunavir/low dose ritonavir with complete resolution following 
their discontinuation has not been reported.
Case Report:
This is a 37 year old female who was started on highly active 
antiretroviral therapy (HAART) with maraviroc, darunavir, 
low dose ritonavir and raltegravir on 
02/19/2008 (CD4-253 cells/ml / HIV 
viral load-17,200copies/ml). At 3 weeks 
CD4 was 446 cells/ml with viral load 
down to 693 copies/ml. At that time she 
complained of low grade fever, sinus 
congestion with maxillary pain, cough 
and headache. This resolved s/p courses 
of TMP/ sulfa and levofloxacin.
On 07/11/2008 she reported 6 pound 
weight gain with new central adiposity 
and mild diffuse alopecia.
Nasal fluticasone was discontinued 
07/30/2008 when she reported significant abdominal 
obesity with breast/posterior cervical fat pad enlargement 
and appearance of fat loss in her 
extremities. A week later she required 
hospital admission for insulin therapy 
for new onset diabetes mellitus type 
2. On 08/07/2008 a dramatic change 
in her appearance was noted with 
facial plethora, bilateral parotid 
fullness, supraclavicular and posterior 
cervical fat pad enlargement and 
central adiposity. She noted easy 
bruisability and was diagnosed with oral 
candidiasis. On 09/02/2008 she required 
insulin adjustment for hemoglobinA1C 
of 9.3%.
On 09/08/2008 she reported ongoing substernal, 
non radiating chest discomfort with facial flushing, 
palpitations and shortness of breath. Work up ruled out 
pheochromocytoma and carcinoid.
The diagnosis of true CS was excluded by an endocrinologist 
with a normal 24 hour urine cortisol and dexamethasone 
suppression test.
On 10/02/2008 after a lengthy discussion with the patient all 
HAART medications were stopped. 
On 10/21/2008 she reported feeling well with marked 
improvement in her Cushingoid appearance. By 11/11/2008 
she was off insulin with hemoglobinA1C down to 6.3%.
On 12/11/2009 she was started on maraviroc, raltegravir and 
etravirine. She has had no recurrence of symptoms, despite 
resumption of maraviroc and raltegravir, 2 of the 3 active 
agents in the regimen she was on when her symptoms first 
occurred.
Discussion:
It is vital that p-CS secondary to PIs therapy is not missed as 
many of the signs/ symptoms are similar to lipodystrophy and 
metabolic disease associated with HIV and HAART and it is 
likely to resolve after discontinuation of the causal agent as in 
this case. Further studies are required to determine if darunavir 
is more likely than other PIs to cause this syndrome.
